Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Spero Therapeutics (SPRO) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to -$7.4 million.

  • Spero Therapeutics' Income from Continuing Operations rose 5828.48% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.4 million, marking a year-over-year decrease of 72916.42%. This contributed to the annual value of -$68.6 million for FY2024, which is 35661.29% down from last year.
  • Latest data reveals that Spero Therapeutics reported Income from Continuing Operations of -$7.4 million as of Q3 2025, which was up 5828.48% from -$1.7 million recorded in Q2 2025.
  • Spero Therapeutics' Income from Continuing Operations' 5-year high stood at $55.1 million during Q4 2023, with a 5-year trough of -$30.1 million in Q1 2022.
  • Moreover, its 5-year median value for Income from Continuing Operations was -$13.9 million (2025), whereas its average is -$10.1 million.
  • As far as peak fluctuations go, Spero Therapeutics' Income from Continuing Operations surged by 20021.88% in 2022, and later crashed by 45402.19% in 2024.
  • Quarter analysis of 5 years shows Spero Therapeutics' Income from Continuing Operations stood at -$27.4 million in 2021, then soared by 200.22% to $27.5 million in 2022, then skyrocketed by 100.51% to $55.1 million in 2023, then tumbled by 137.03% to -$20.4 million in 2024, then skyrocketed by 63.82% to -$7.4 million in 2025.
  • Its Income from Continuing Operations stands at -$7.4 million for Q3 2025, versus -$1.7 million for Q2 2025 and -$13.9 million for Q1 2025.